Overview

Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)

Status:
Active, not recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The investigators aim to demonstrate that ramipril after transcatheter aortic valve implantation has benefits in terms of prognosis, cardiovascular events and ventricular remodeling (MRI).

Phase:

Phase 4

Details

Lead Sponsor:

Hospital Clínico Universitario de Valladolid
Luis Varela-Falcon

Collaborator:

Hospital Clínico Universitario de Valladolid

Treatments:

Ramipril